Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.

Earnings